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Aims: A pilot study was undertaken with the aim of documenting acute skin reactions and 2-year late adverse effects of
a five-fraction course of adjuvant whole breast radiotherapy delivered over 15 days after local tumour excision of early
breast cancer.
Materials and methods: Thirty women with early invasive breast cancer aged R50 years with a pathological tumour
size !3 cm, complete microscopic resection, negative axillary node status and no requirement for cytotoxic therapy
were prescribed 30 Gy in five fractions over 15 days to the whole breast using tangential 6e10 MV X-ray beams and
three-dimensional dose compensation with written informed consent. Post-surgical baseline photographs of the breasts
were taken, and acute skin erythema and moist desquamation were each scored weekly for 7 weeks using four-point
graded scales (grade 0[ none, 1[mild, 2[moderate, 3[ severe). This was followed by an annual clinical assessment,
including repeat photographs at 2 years.
Results: Nine patients (30%, 95% confidence interval 14.7e49.4%) developed grade 2 erythema, with the remaining 21
patients developing milder degrees of reaction. Four (13.3%, 95% confidence interval 3.7e30.7) patients developed
moist desquamation, grade 1 in three women and grade 2 in the fourth. At 2 years after treatment, 23/30 (77%) patients
scored no change in photographic breast appearance compared with the pre-treatment baseline; seven (23%, 95%
confidence interval 9.9e42.3) scored a mild change in breast appearance, and none developed a marked change. After
a mean follow-up of 3.1 years (standard deviation 0.37, range 2.1e3.9 years) there have been no ipsilateral local tumour
relapses.
Conclusions: Further evaluation of a five-fraction regimen of adjuvant whole breast radiotherapy in a phase III
randomised trial is justified, including a regimen delivered in a total of 5 days. Martin, S. et al. (2008). Clinical Oncology
20, 502—505
ª 2008 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
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Interest in hypofractionation for adjuvant breast radiother-
apy re-emerged in the mid-1980s after a re-analysis of
historical data, using the linear-quadratic model, suggested
that breast cancer is as sensitive to fraction size as the
dose-limiting late responding normal tissues [1,2]. Two
prospective randomised trials subsequently reported re-
sults consistent with this suggestion, including the Royal
Marsden NHS Foundation Trust/Gloucestershire Oncology
Centre (RMH/GOC) trial, which tested two dose levels of
a 13-fraction regimen over 5 weeks against 50 Gy in 25
fractions, and the Ontario trial, which tested a 16-fraction
regimen over 3.2 weeks against 50 Gy in 25 fractions [3e5].
Subsequently, the UK Standardisation of Breast Radiotherapy0936-6555/08/200502þ04 $35.00/0 ª 2008 The Royal Col(START) trials tested two 13-fraction schedules over 5
weeks and 40 Gy in 15 fractions over 3 weeks, each against
50 Gy in 25 fractions over 5 weeks. The 5-year results of the
START trials are also consistent with the hypothesis that
breast cancer has a comparable sensitivity to fraction size
as the late responding normal tissues of the breast [6]. If
true, it means that the current use of small fraction sizes
spares the tumour as effectively as the late responding
normal tissues.
Thirteen-, 15- or 16-fraction schedules are unlikely to
represent the limits of hypofractionation. To explore this
further, the UK National Cancer Research Network FAST
trial randomised 900 patients to five fractions of 5.7 Gy
or 6.0 Gy delivered in 5 weeks vs 25 fractions of 2.0 Gy
with late adverse effects as primary end points [7]. Thelege of Radiologists. Published by Elsevier Ltd. All rights reserved.
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a future phase III randomised trial of a five-fraction regimen
delivered in 5 days, a pilot study evaluated erythema and
moist desquamation in patients receiving 30 Gy in five
fractions delivered twice weekly to the whole breast in 15
days. This intermediate time period was chosen to be sure
of complete cellular recovery between fractions (minimum
48 h). The early results of this experience are reported
here.Materials and Methods
PatientsPatients eligible for entry into this pilot study were women
aged R 50 years after breast conservation surgery for
invasive breast carcinoma with a pathological tumour size
!3 cm, complete microscopic resection, no lymphovascular
invasion, negative axillary node status and no requirement
for neoadjuvant or adjuvant cytotoxic therapy.RadiotherapyPatients were treated in the supine position, with both
arms abducted at 90. The reproducibility of positioning
was verified by orthogonal laser beams. The planning target
volume was defined as the entire breast with a 1 cm margin
to palpable breast tissue. The reference point for dose
prescription was chosen according to International Com-
mission on Radiation Units (ICRU 50) guidelines. Dose
homogeneity complied with ICRU 50 recommendations.
Full-dose compensation was delivered using multiple static
fields [8] if the maximum dose was O105%. Megavoltage 6
or 10 MV photons were used in all patients. No tumour bed
boost was delivered to any patient.Assessment of Normal Tissue ReactionsFig. 1 e (a) Maximum grade of erythema developing in 30 patients
receiving 30 Gy in five fractions over 5 weeks to the whole breast.
(b) Grade and duration of moist desquamation developing in 4/30
women receiving 30 Gy in five fractions over 5 weeks to the whole
breast.Clinical assessments of early normal tissue reaction were
carried out once weekly during radiotherapy and for 5
weeks after the end of treatment (7 weeks overall). These
recorded the degree of erythema and moist desquamation
on four-point graded scales (grade 0¼ none, 1¼mild,
2¼moderate, 3¼ severe) on case report forms. The maxi-
mum orthogonal dimensions of moist desquamation were
also recorded.
Patients consented to have frontal photographs taken of
their breasts before radiotherapy and 2 years after
treatment under standard conditions. Pairs of photographs
were taken, one with both arms on hips and a second
with both arms raised above the head. Additional photo-
graphs were also collected in selected patients with acute
skin reactions R grade 2 erythema. A change in breast
appearance compared with the baseline before radiother-
apy photographs was scored on a three-point graded scale
(0¼ no change, 1¼mild change, 2¼marked change) by
two observers (LG and JY). Breast size was also assessed
from the baseline photographs on a three-point scale
(small, medium, large).Statistical MethodsThe sample size for this pilot study was chosen to be 30
patients on the grounds of feasibility rather than statistical
considerations. Considering a rate of moist desquamation
%20%, this sample size is associated with a standard error
%7%. The percentages of patients experiencing erythema
and moist desquamation and change in breast appearance
(photographic) at 2 years were calculated with exact 95%
confidence intervals.Results
Written informed consent to participate in the pilot study
was obtained from 30 patients between March 2004 and
March 2005. Nine (30%) patients required three-dimensional
radiotherapy dose compensation, delivered using multiple
static fields. No cases of grade 3 erythema were seen,
although one patient was downgraded from grade 3 to grade
2 (moderate) after reviewing a photograph of the peak
reaction. Nine (30%, 95% confidence interval 14.7e49.4%)
patients developed grade 2 erythema that subsided in eight
patients to grade 1 or less within 2 weeks. In the ninth
patient, grade 2 erythema settled within 3 weeks. The
maximum erythema scores are summarised in Fig. 1a. Four
(13.3%, 95% confidence interval 3.7e30.7) patients de-
veloped moist desquamation, grade 1 in three women and
grade 2 in the fourth (see Fig. 1b). The maximum dimension
in these four cases ranged from 5 to 50 mm; all lesions
developed in the inframammary fold or axilla. Moist
desquamation healed within 2 weeks in three of the four
Table 1 e Early skin reactions and late change in breast
appearance (scored from baseline and 2-year photographs)










at 2 years (%)
Small 3/14 (21.4) 1/14 (7.1) 2/14 (14.3)
Medium 5/13 (38.5) 2/13 (15.4) 4/13 (30.8)
Large 1/3 (33.3) 1/3 (33.3) 1/3 (33.3)
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scored no change in photographic breast appearance
compared with the before treatment baseline; seven (23%,
95% confidence interval 9.9e42.3) scored mild change in
breast appearance, and none developed marked change.
From the baseline photographs, breast size was recorded as
small in 14 (46.7%), medium in 13 (43.3%) and large in three
(10%) women. There was some evidence that the risk of
acute skin reactions and change in breast appearance
(photographic) increased with larger breast size, but the
small sample size prevented formal statistical testing (see
Table 1). To date, there have been no ipsilateral local
tumour relapses over a mean follow-up of 3.1 years
(standard deviation 0.37, range 2.1e3.9 years).Discussion
The early and 2-year normal tissue responses scored in this
pilot study were generally very mild, and not different from
those expected after standard regimens. A reliable com-
parison of these effects after 30 Gy in five fractions over 15
days with the effects of 50 Gy in 25 fractions is limited by
the lack of a randomised comparator group. A Radiation
Therapy Oncology Group trial (RTOG 97-13) testing sup-
portive care of skin toxicity in women undergoing breast
radiotherapy, combined with the results of previous RTOG
experience, reported 7% grade 0, 58% grade 1, 32% grade 2,
3% grade 3, and no grade 4 acute skin toxicity [9].
Retrospective re-grading of skin reactions in the present
pilot study, applying RTOG criteria, produced comparable
rates: 3% grade 0, 67% grade 1, 30% grade 2 and no grade 3
or 4 toxicity. However, differences in breast size and
radiation dosimetry limit the reliability of this comparison
[10,11]. A correlation between breast size and acute
toxicity was reported in the RTOG 97-13 study, with
small-breasted women developing 11e21% grade 2 or higher
skin toxicity compared with 43e50% in large-breasted
women. There was some evidence of a similar association
between acute and late toxicity and breast size in the pilot
study, but numbers were too small for formal statistical
testing.
Changes in breast appearance 2 years after treatment
were very mild, and comparable with the 2-year rates
reported after 50 Gy in 25 fractions in the RMH/GOC andSTART trials [3,6]. However, the same limitations apply to
this comparison as discussed for acute skin toxicities. In
addition, the nine (30%) patients in the pilot study treated
with full (three-dimensional) dose compensation may have
developed slightly lower levels of late normal tissue effects
than if standard two-dimensional dosimetry had been used
[10,11]. Late changes in normal tissues are also more
sensitive to fraction size than early skin reactions [12]. A
meta-analysis of the RMH/GOC and NCRI START trials
generated an a/b value of 3.4 Gy for late adverse effects,
making the present dose schedule equivalent to a total
dose of 52 Gy in 2.0 Gy fractions. This estimate assumes
complete repair between fractions, whereas it is clear that
this is incomplete in human skin even after 24 h [13]. If an
incomplete repair model is applied, 30 Gy in five fractions
over 5 days is expected to be equivalent to 50 Gy in 2.0 Gy
fractions [14].
The longer term aim is to explore a whole breast
radiotherapy schedule of five fractions delivered in 5 days
in a randomised clinical trial. It is not expected that
reducing the overall treatment time from 15 to 5 days will
enhance acute skin reactions, as accelerated repopulation
in basal epidermis starts only after 15 days, but a small dose
adjustment may be needed to compensate for incomplete
repair [15]. Where late effects are concerned, long-term
follow-up of a large number of patients will be needed for
full evaluation.Acknowledgement. The authors wish to acknowledge the help-
ful advice of Professor John Hopewell in the preparation of this
manuscript.
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